Status:
ACTIVE_NOT_RECRUITING
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Ono Pharmaceutical Co. Ltd
Conditions:
Stomach Neoplasms
Eligibility:
All Genders
20+ years
Brief Summary
The purpose of this study is to assess the effectiveness, safety, and actual treatment status of first-line nivolumab plus chemotherapy in participants with untreated advanced / recurrent gastric canc...
Detailed Description
The Time Perspective for this observational study is defined as 'Retrospective and Prospective'.
Eligibility Criteria
Inclusion
- Histologically confirmed advanced or recurrent gastric cancer
- Have initiated or are confirmed to receive nivolumab plus chemotherapy as the first-line therapy between the date of approval of nivolumab plus chemotherapy and December 31, 2022. For combination chemotherapy, SOX, CapeOX, or FOLFOX is acceptable
- Have signed a written informed consent form of their own free will after they have been given an adequate explanation and a full understanding of this study before enrolling in this study.
Exclusion
- Treated with antineoplastic agents as first-line treatment for advanced or recurrent gastric cancer prior to the initiation of nivolumab plus chemotherapy (participants who have received prior perioperative chemotherapy and participants who have received prior bisphosphonates for osseous metastases may be enrolled)
- Confirmed to be positive for HER2
- Diagnosed with gastric cancer and have previously received investigational drugs with anti-tumor effects
- Initiated with nivolumab plus chemotherapy as the first-line treatment for advanced or recurrent gastric cancer at a site other than the study site and were later hospitalized at the study site.
- Judged by the investigators to be inappropriate for enrollment in this study
Key Trial Info
Start Date :
June 29 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05334719
Start Date
June 29 2022
End Date
September 30 2026
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Minato-ku, Tokyo, Japan, 1050001